Thr82
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr82  -  RXRA (human)

Site Information
HSMsVPTtPTLGFST   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 453096

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 2 ) , mutation of modification site ( 1 , 2 ) , phospho-antibody ( 2 ) , western blotting ( 2 )
Disease tissue studied:
liver cancer ( 2 ) , hepatocellular carcinoma ( 2 ) , prostate cancer ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Treatments:
1,25_dihydroxyvitamin_D ( 1 )

Downstream Regulation
Effects of modification on RXRA:
molecular association, regulation ( 1 , 2 )
Effects of modification on biological processes:
apoptosis, inhibited ( 2 ) , carcinogenesis, induced ( 2 ) , cell growth, induced ( 2 ) , transcription, inhibited ( 1 , 2 )
Inhibit interaction with:
RARB (human) ( 2 ) , RXRA (human) ( 2 ) , SRC-1 (human) ( 1 )

References 

1

Zhang Z, et al. (2010) Constitutive activation of the mitogen-activated protein kinase pathway impairs vitamin D signaling in human prostate epithelial cells. J Cell Physiol 224, 433-42
20432439   Curated Info

2

Yoshimura K, et al. (2007) Phosphorylated retinoid X receptor alpha loses its heterodimeric activity with retinoic acid receptor beta. Cancer Sci 98, 1868-74
17900311   Curated Info